Trial

• Signed and dated informed consent forms (per subject)
• Delegation log and training records
• Source documents (e.g., medical records)
• Case Report Forms (CRFs)
• Monitoring visit reports and deviation logs
• Investigational product accountability logs
• SAE reports and Data Safety Monitoring Board (DSMB) reports

3. After Completion or Termination

• Final study report
• Archiving of TMF (Trial Master File)
• Notification of trial close-out to regulators and IRBs

Trial Master File (TMF) and Investigator Site File (ISF)

• TMF: Maintained by sponsor or CRO, includes all essential trial documentation
• ISF: Maintained at each site, includes site-specific documentation
• Both should be inspection-ready at all times

GCP Monitoring Requirements in Phase 2

1. Site Initiation Visits (SIV)

• Verify regulatory documents and site readiness
• Train site personnel on protocol and GCP

2. Routine Monitoring Visits

• Ensure protocol adherence and data verification
• Review ICFs, AE reporting, and IP accountability

3. Close-out Visits

• Ensure document archiving and final IP reconciliation
• Site sign-off on final CRFs and reports

Documentation of Protocol Deviations

• Deviations must be recorded, assessed, and reported
• Major deviations (e.g., enrollment violations, missed primary endpoint visits) require justification and notification to the IRB

Audit and Inspection Preparedness

• Maintain an audit trail of all changes to data and documents
• Prepare summary logs (e.g., AE log, deviation log, visit log)
• Ensure consistency between source data and CRFs
• Conduct internal audits to ensure GCP compliance before external inspections

Common GCP Compliance Issues in Phase 2

• Incomplete or missing informed consent documentation
• Untimely AE/SAE reporting
• Failure to document protocol deviations
• Outdated investigator brochures and protocol versions

Regulatory Expectations by Region

FDA (U.S.)

• Conducts BIMO (Bioresearch Monitoring Program) inspections during Phase 2
• Requires prompt SAE reporting and adequate site oversight

EMA (EU)

• Emphasizes TMF completeness under EU Clinical Trials Regulation
• Mandates GCP compliance audits prior to marketing application

PMDA (Japan)

• Expects clear SOPs for documentation handling
• Focuses on eSource and eCRF audit trail integrity

CDSCO (India)

• Requires compliance with Schedule Y and ICH E6 GCP
• Inspections include investigator qualification and documentation standards

Best Practices for Documentation and Compliance

• Use standardized SOPs for documentation across sites
• Implement electronic systems (eTMF, eISF) with audit trails
• Train all staff in GCP and documentation expectations
• Perform ongoing QC checks for missing or inconsistent records

Conclusion

Proper documentation and adherence to GCP are non-negotiable in Phase 2 clinical trials. They form the backbone of regulatory submission, ethical conduct, and trial integrity. By maintaining well-organized essential documents, monitoring sites effectively, and ensuring staff are GCP-trained, sponsors and investigators can confidently advance drug development while remaining compliant with global regulatory expectations.